NRX Pharmaceuticals, Inc. (NRXPW) Financial Statements (2026 and earlier)

Company Profile

Business Address 1201 ORANGE STREET
WILMINGTON, DE 19801
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,443,0004,595,00020,054,00027,605,0004666
Cash and cash equivalent1,443,0004,595,00020,054,00027,605,0004666
Prepaid expense1,035,0001,205,0003,498,0003,569,00030,35069,483
Other undisclosed current assets824,0001,084,0002,243,0001,540,00051,642 
Total current assets:3,302,0006,884,00025,795,00032,714,00082,45869,489
Noncurrent Assets
Asset, held-in-trust     5,967,94732,005,205
Other noncurrent assets349,000431,00021,00015,000  
Total noncurrent assets:349,000431,00021,00015,0005,967,94732,005,205
TOTAL ASSETS:3,651,0007,315,00025,816,00032,729,0006,050,40532,074,694
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8,909,0009,346,0006,931,0006,062,000609,509622,441
Accounts payable4,130,0004,632,0002,076,0003,687,000  
Accrued liabilities4,779,0004,714,0004,855,0002,375,000  
Other undisclosed accounts payable and accrued liabilities     609,509622,441
Deferred revenue    292,000  
Debt1,566,0009,161,000  1,809,889 
Derivative instruments and hedges, liabilities5,639,00017,00037,000 655,098 
Customer refund liability4,715,000     
Business combination, contingent consideration, liability    4,582,000  
Due to related parties  862,148 
Other undisclosed current liabilities1,034,000524,0008,617,000987,000  
Total current liabilities:21,863,00019,048,00015,585,00011,923,0003,936,644622,441
Noncurrent Liabilities
Long-term debt and lease obligation 5,011,000    1,535,623
Long-term debt, excluding current maturities 5,011,000    1,535,623
Liabilities, other than long-term debt      416,141
Due to related parties   416,141
Other undisclosed noncurrent liabilities   2,822,000   
Total noncurrent liabilities: 5,011,000 2,822,000  1,951,764
Total liabilities:26,874,00019,048,00018,407,00011,923,0003,936,6442,574,205
Temporary equity, including noncontrolling interest      24,500,488
Equity
Equity, attributable to parent, including:(23,223,000)(11,733,000)7,409,00020,806,0002,113,7615,000,001
Common stock15,00084,00067,00059,0002,6882,844
Additional paid in capital255,035,000241,330,000230,339,000203,990,0002,831,0884,627,662
Accumulated other comprehensive loss  (3,000)    
Retained earnings (accumulated deficit)(278,273,000)(253,147,000)(222,997,000)(183,243,000)(720,015)369,495
Other undisclosed equity, attributable to parent  3,000    
Total equity:(23,223,000)(11,733,000)7,409,00020,806,0002,113,7615,000,001
TOTAL LIABILITIES AND EQUITY:3,651,0007,315,00025,816,00032,729,0006,050,40532,074,694

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(18,502,000)(27,837,000)(44,335,000)(115,796,000)(907,406)(713,187)
Operating loss:(18,502,000)(27,837,000)(44,335,000)(115,796,000)(907,406)(713,187)
Nonoperating income (expense)(6,624,000)(2,313,000)4,581,00022,733,000(164,263) 
Interest and debt expense(230,000)(120,000) 121,000352,071 
Loss from continuing operations before equity method investments, income taxes:(25,356,000)(30,270,000)(39,754,000)(92,942,000)(719,598)(713,187)
Other undisclosed income (loss) from continuing operations before income taxes    (121,000)(352,071)1,205,820
Income (loss) from continuing operations before income taxes:(25,356,000)(30,270,000)(39,754,000)(93,063,000)(1,071,669)492,633
Income tax expense  (2,850,000)  (17,841)(84,206)
Income (loss) from continuing operations:(25,356,000)(33,120,000)(39,754,000)(93,063,000)(1,089,510)408,427
Income (loss) before gain (loss) on sale of properties:(93,063,000)(1,089,510)408,427
Other undisclosed net income  2,970,000    
Net income (loss):(25,356,000)(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,427
Other undisclosed net income (loss) attributable to parent230,000     
Net income (loss) attributable to parent:(25,126,000)(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,427
Other undisclosed net loss available to common stockholders, basic    (255,822,000) (703,894)
Net loss available to common stockholders, diluted:(25,126,000)(30,150,000)(39,754,000)(348,885,000)(1,089,510)(295,467)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(25,356,000)(30,150,000)(39,754,000)(93,063,000)(1,089,510)408,427
Other comprehensive income (loss) 30,153,000    
Other undisclosed comprehensive income      
Comprehensive income (loss):(25,356,000)3,000(39,754,000)(93,063,000)(1,089,510)408,427
Other undisclosed comprehensive income, net of tax, attributable to parent 230,000     
Comprehensive income (loss), net of tax, attributable to parent:(25,126,000)3,000(39,754,000)(93,063,000)(1,089,510)408,427

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: